Lupin Limited has received final approval from the US Food and Drug Administration to market its generic Pitolisant tablets. This treatment for excessive daytime sleepiness follows the resolution of patent litigation, clearing the path for commercial launch. The development is supported by the company's recent strong financial performance and net cash position as of June 2026.
Mumbai-based pharmaceutical company Lupin Limited has secured final approval from the US Food and Drug Administration for its generic version of Pitolisant tablets. The approval covers the 4.45 mg and 17.8 mg strengths of the medication, which is used to treat excessive daytime sleepiness. This is a notable development for the company as it moves to commercialize a product that was previously held under tentative approval since March 2026.
The regulatory clearance marks the resolution of patent litigation hurdles that had previously restricted the company from fully entering the US market with this specific product. By receiving this final nod, Lupin can now move forward with the distribution of its generic version, which is bioequivalent to Wakix, a drug currently marketed by Harmony Biosciences. The tablets are manufactured at the company’s facility in Nagpur, India.
From a financial perspective, Lupin enters this launch phase with a stable balance sheet. As of the quarter ending June 30, 2026, the company reported a net cash position, with net debt recorded at approximately negative INR 28,308 million. The company also demonstrated strong operational performance in the first quarter of fiscal year 2027, with revenue exceeding INR 8,000 crore. This financial flexibility supports the company's ability to allocate resources for the manufacturing and distribution of new products.
While the approval is a step forward, the pharmaceutical sector carries inherent operational risks. Investors typically monitor ongoing regulatory scrutiny from the US health regulator, as any concerns regarding manufacturing compliance at facilities can disrupt supply chains. Furthermore, because Lupin generates a significant portion of its total revenue from the United States, the company remains sensitive to fluctuations in the US generic drug market, including pricing pressure and the entry of competing products.
The next steps for the company will involve the timeline for the commercial launch of these tablets in the United States. Investors and analysts will likely track how quickly the company can penetrate the market and gain traction against existing offerings. Maintaining high manufacturing standards at its Indian facilities will remain a key operational priority to ensure a steady and reliable supply of the drug to the US market.